Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 >= 50% and without actionable genomic alterations.
Datopotamab Deruxtecan;Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 >= 50% and without actionable genomic alterations. ### Output: Datopotamab Deruxtecan;Pembrolizumab